Age-stratified clinical characteristics of hand, foot, and mouth disease in children and its guiding value for diagnosis and treatment - Scorecard - MDSpire
Advertisement
Age-stratified clinical characteristics of hand, foot, and mouth disease in children and its guiding value for diagnosis and treatment
Clinical Scorecard: Clinical Features of Hand, Foot, and Mouth Disease in Children: An Age-Based Analysis and Its Implications for Diagnosis and Treatment
At a Glance
Category
Detail
Condition
Hand, Foot, and Mouth Disease (HFMD)
Key Mechanisms
Caused by enteroviruses, with clinical manifestations ranging from mild to severe, including neurological complications.
Target Population
Children under 5 years of age, with a focus on age-stratified differences.
Care Setting
Pediatric infectious disease management in a hospital setting.
Key Highlights
Children aged 1–3 years accounted for 62.76% of cases.
Neonates showed higher CSF protein and lower glucose levels.
Convulsions were most frequent in the 1–3 years age group.
Older children had higher rates of intracranial hypertension.
Age-specific diagnostic and management strategies are recommended.
Guideline-Based Recommendations
Diagnosis
Utilize age-stratified clinical profiles for HFMD diagnosis.
Management
Implement age-specific management strategies to improve outcomes.
Monitoring & Follow-up
Monitor CSF abnormalities and peripheral inflammatory markers.
Risks
Be aware of the increased risk of neurological complications in older children.
Patient & Prescribing Data
Pediatric patients with HFMD, particularly those under 5 years.
Treatment should consider age-related clinical features and potential complications.
Clinical Best Practices
Conduct thorough clinical assessments based on age groups.
Monitor for signs of neurological involvement, especially in older children.
Utilize laboratory findings to guide treatment decisions.
Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
